Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Deucravacitinib (BMS-986165) in the Treatment of Pityriasis Rubra Pilaris

NCT06444399 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06444399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06444399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Deucravacitinib (BMS-986165) in the Treatment of Pityriasis Rubra Pilaris
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
July 29, 2024
Completion date
May 1, 2026
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pityriasis rubra pilaris